Phase 2 Start
IBO: Phase 2 Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy an
December 1, 2026. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- December 1, 2026
- Company
- IMPACT BIOMEDICAL INC. (IBO)
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 2 Start~month
Phase 2 Start: A Phase II, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy an
- Company
- IMPACT BIOMEDICAL INC. (IBO)
- Indication
- Parkinson's Disease (PD)